High-strength testosterone undecanoate compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C max to serum testosterone C ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C ave range for a male subject is provided.
1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
Orally administering to said male a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier, that provides about 450 mg of testosterone undecanoate to said male per day to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL.
2. The method of claim 1 wherein said pharmaceutical carrier comprise a solubilizer and a dispersant.
3. The method of claim 1 wherein said pharmaceutical carrier comprises a solidifying agent.
4. The method of claim 1 wherein said pharmaceutical carrier comprises a monoglyceride.
5. The method of claim 1 wherein said pharmaceutical carrier comprises a diglyceride.
6. The method of claim 1 wherein said pharmaceutical carrier comprises a triglyceride.
7. The method of claim 1 wherein said pharmaceutical carrier comprises a fatty acid.
8. The method of claim 1 wherein said pharmaceutical carrier comprises medium chain monoglycerides and diglycerides.
9. The method of claim 1 wherein said pharmaceutical carrier comprises a tocopherol.
10. The method of claim 1 wherein said carrier comprises a hydrophilic surfactant.
11. The method of claim 1 wherein said orally administering is twice a day.
12. The method of claim 1 wherein said orally administering is three times a day.
13. The method of claim 1 wherein said pharmaceutical composition has at least 5% of the testosterone undecanoate not dissolved and at least 35% dissolved in said carrier.
14. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
Orally administering to said male a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier, that provides about 450 mg of testosterone undecanoate to said male per day to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL, wherein said pharmaceutical composition has at least 5% of the testosterone undecanoate not dissolved and at least 35% dissolved in said carrier.
15. The method of claim 14 wherein said orally administering is twice a day.
16. The method of claim 14 wherein said orally administering is three times a day.
17. The method of claim 14 wherein said carrier has one or more of the following: a fatty acid, a monoglyceride, a diglyceride, a triglyceride, and a tocopherol.
18. The method of claim 14 wherein said carrier has a hydrophilic surfactant.
19. The method of claim 14 wherein said carrier has a solidifying agent.